Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 32 Issue 1
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2014  >  32(1): 1-4,8

ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu

Research progress in the combined use of amphotericin B

doi: 10.3969/j.issn.1006-0111.2014.01.001

  • The Center of New Drug Development, Second Military Medical University, Shanghai 200433, China

  • Received Date: 2013-03-12
  • Rev Recd Date: 2013-09-02
  • Objective Amphotericin B (AmB) was a polyene antifungal agent. Because of its lowest resistance rate and broad antibiotic spectrum, AmB was considered as a "gold standard" for the treatment of deep fungal infections. However, the occurrence of toxicity and serious side effects, especially renal toxicity, greatly limited the application of AmB in clinical antifungal therapy. Due to the lack of antifungal with high efficiency and low toxicity, the combination of antifungal agents with different mechanisms of action was a promising research direction. The advantage of the combinations was the course of treatment shortened, drug side effects reduced, the antibacterial spectrum expanded, and drug resistance avoided. The research progress in the combined use of AmB with different types of antifungal compounds were introduced in this article.
  • [1] Montoya JG,Rosso F. Is combination therapy indicated for invasive fungal infections?Yes and no[J].Curr Opin Infect Dis,2006,19(4):371-379.
    [2] Nivoix Y,Zamfir A,Lutun P,et al,Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections[J].J Infect,2006,52(1):67-74.
    [3] Kontoyiannis DP,Lewis RE.Combination chemotherapy for invasive fungal infections:what laboratory and clinical studies tell us so far[J].Drug Resist Updat,2003,6(1):257-269.
    [4] Mukherjee PK,Sheehan DJ,Hitchcock CA,et al.Combination treatment of invasive fungal infections[J].Clin Microbiol Rev,2005,18(1):163-194.
    [5] Chamilos G,Kontoyiannis DP.The rationale of combination antifungal therapy in severely immuncompromised patients:empiricism versus evidence-based medicine[J].Curr Opin Infect Dis,2006,19(4):380-385.
    [6] Marr KA,Boeckh M,Carter RA,et al.Combination antifungal therapy for invasive aspergillosis[J].Clin Infect Dis,2004,39(6):797-802.
    [7] Matsuoka S, Murata M. Cholesterol markedly reduces ion permeability induced by membrane-bound amphotericin B[J]. Biochim Biophys Acta, 2002,1564(2):429-434.
    [8] Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity:a review[J]. J Chemother, 2000,12(6):463-470.
    [9] Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:animal experiments and clinical study[J]. J Infect Dis 2002,186(3):379-388.
    [10] Louie A, Kaw P, Banerjee P,et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis[J].Antimicrob Agents Chemother, 2001, 45(2):485-494.
    [11] Samaranayake YH, Samaranayake LP, Yeung KW. Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J].Chemotherapy, 2001, 47(4):279-291.
    [12] Barchiesi F, Schimizzi AM, Caselli F,et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2000, 44(9):2435-2441.
    [13] Popp AI, White MH, Quadri T,et al. Amphotericin B with and without itraconazole for invasive aspergillosis. A three-year retrospective study[J].Int J Infect Dis, 1999, 3(3):157-160.
    [14] Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species[J].MedMycol, 2001, 39(1):91-95.
    [15] Rodero L, Cordoba S, Cahn, P,et al. In vitro susceptibility studies of Cryptococcus Neoformans isolated from patients with no clinical response to amphotericin B therapy[J].J Antimicrob Chemother,2000, 45(2):239-242.
    [16] Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
    [17] Sevtap Arikan, Mario Lozano-Chiu,Victor Paetznick, et al.In vitro synergy of caspofungin and amphotericin B Against Aspergillus and Fusarium spp[J].Antimicrob Agents Chemother,2002, 46(1):245-247.
    [18] Jon AO, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin[J]. Antimicrob Agents Chemother,2005, 49 (12):4895-4902.
    [19] Francesco B,Elisabetta S,Serena T, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemoth, 2007, 51(3):941-945.
    [20] Ogita A, Hirooka K, Yamamoto Y, et al. Synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, and its relation to the role of alkyl hydroperoxide reductase 1 as a cell surface defense in Saccharomyces cerevisiae[J]. Toxicology,2005,215(3):205-13.
    [21] Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-304.
    [22] An M, Shen H, Cao Y, et al.Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agents. 2009; 33(3):258-63.
    [23] Cao YY,Dai BD, Wang Y, et al.In vitro activity of baicalein against Candida albicans biofilms[J]. Int J Antimicrob Agents, 2008,32:73-77.
    [24] Huang S, Cao YY, Dai BD, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.Biol Pharm Bull, 2011,31:2234-2236.
    [25] Fu ZJ, Lu H,Zhu ZY, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull,2011,34(2):214-218.
    [26] Phillips AJ, Sudbery I, Ramsdale M.Apoptosis induced by environmental stresses and amphotericin B in Candida albicans[J]. Proc Natl Acad Sci,2003,100:14327-14332.
    [27] Phillips AJ, Crowe JD, Ramsdale M.Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans[J].Proc Natl Acad Sci,2006,103:726-731.
    [28] Cao YY,HuangS, Dai BD, et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46:183-189.
    [29] Clancy CJ, Wingard JR, Hong-Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients:review of the literature and demonstration of invitro synergy between antifungal agents[J].Med Mycol, 2000, 38(2):169-175.
    [30] Ellis M, Watson R, McNabb A,et al. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery[J].J Med Microbiol,2002, 51(1):70-75.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3008) PDF downloads(135) Cited by()

Related
Proportional views

Research progress in the combined use of amphotericin B

doi: 10.3969/j.issn.1006-0111.2014.01.001
  • The Center of New Drug Development, Second Military Medical University, Shanghai 200433, China
  • Received Date: 2013-03-12
  • Rev Recd Date: 2013-09-02

Abstract: Objective Amphotericin B (AmB) was a polyene antifungal agent. Because of its lowest resistance rate and broad antibiotic spectrum, AmB was considered as a "gold standard" for the treatment of deep fungal infections. However, the occurrence of toxicity and serious side effects, especially renal toxicity, greatly limited the application of AmB in clinical antifungal therapy. Due to the lack of antifungal with high efficiency and low toxicity, the combination of antifungal agents with different mechanisms of action was a promising research direction. The advantage of the combinations was the course of treatment shortened, drug side effects reduced, the antibacterial spectrum expanded, and drug resistance avoided. The research progress in the combined use of AmB with different types of antifungal compounds were introduced in this article.

ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu

    HTML

Reference (30)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return